notch1 signaling (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
97
Structured Review
MedChemExpress
notch1 signaling
Notch1 Signaling, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/notch1+signaling+inhibitor+dapt/DAPT/pm41962853-255-8-13
Average 97 stars, based on 153 article reviews
Notch1 Signaling, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/notch1+signaling+inhibitor+dapt/DAPT/pm41962853-255-8-13
Average 97 stars, based on 153 article reviews
notch1 signaling - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Control:Article Title: NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Article Snippet: .. When the average tumor volume reached 100 mm3, the mice were randomly allocated into six groups according to the administration regimen: Control (normal saline), Article Title: NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors Article Snippet: .. When the average tumor volume reached 100 mm 3 , the mice were randomly allocated into six groups according to the administration regimen: Control (normal saline), Saline:Article Title: NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Article Snippet: .. When the average tumor volume reached 100 mm3, the mice were randomly allocated into six groups according to the administration regimen: Control (normal saline), Article Title: NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors Article Snippet: .. When the average tumor volume reached 100 mm 3 , the mice were randomly allocated into six groups according to the administration regimen: Control (normal saline), Cell Culture:Article Title: LFA-1/ICAM-1 Interactions Between CD8 + and CD4 + T Cells Promote CD4 + Th1-Dominant Differentiation and CD8 + T Cell Cytotoxicity for Strong Antitumor Immunity After Cryo-Thermal Therapy Article Snippet: CD4 + and CD8 + T lymphocytes extracted from CTT-treated mice on the fifth day post-CTT were cocultured at a 2:1 effector-to-target ratio for 24 h. The T cells were stimulated using the anti-CD3a antibody (1 μg/mL, Biolegend, San Diego, CA, USA, Clone 145-2C11). .. To explore the interaction mechanism between CD4 + and CD8 + T cells, the cells were separately cultured in 0.4 μm Transwell chambers, or the following were added: CD11a (LFA-1alpha) monoclonal antibody (5 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone M17/4), CD54 (ICAM-1) monoclonal antibody (10 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone YN1/1.7.4), recombinant mouse IL-2 (100 IU/mL, novoprotein, Suzhou, China, P04351), InVivoMAb anti-mouse IL-2 (15 μg/mL, Bioxcell, Lebanon, NH, USA, Clone JES6-5H4), STAT5 inhibitor BD750 (10 μM, MedChemExpress, Monmouth Junction, NJ, USA), or Article Title: LFA-1/ICAM-1 Interactions Between CD8 + and CD4 + T Cells Promote CD4 + Th1-Dominant Differentiation and CD8 + T Cell Cytotoxicity for Strong Antitumor Immunity After Cryo-Thermal Therapy. Article Snippet: CD4+ and CD8+ T lymphocytes extracted from CTT-treated mice on the fifth day post-CTT were cocultured at a 2:1 effector-to-target ratio for 24 h. The T cells were stimulated using the anti-CD3a antibody (1 μg/mL, Biolegend, San Diego, CA, USA, Clone 145-2C11). .. To explore the interaction mechanism between CD4+ and CD8+ T cells, the cells were separately cultured in 0.4 μm Transwell chambers, or the following were added: CD11a (LFA-1alpha) monoclonal antibody (5 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone M17/4), CD54 (ICAM-1) monoclonal antibody (10 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone YN1/1.7.4), recombinant mouse IL-2 (100 IU/mL, novoprotein, Suzhou, China, P04351), InVivoMAb anti-mouse IL-2 (15 μg/mL, Bioxcell, Lebanon, NH, USA, Clone JES6-5H4), STAT5 inhibitor BD750 (10 μM, MedChemExpress, Monmouth Junction, NJ, USA), or Recombinant:Article Title: LFA-1/ICAM-1 Interactions Between CD8 + and CD4 + T Cells Promote CD4 + Th1-Dominant Differentiation and CD8 + T Cell Cytotoxicity for Strong Antitumor Immunity After Cryo-Thermal Therapy Article Snippet: CD4 + and CD8 + T lymphocytes extracted from CTT-treated mice on the fifth day post-CTT were cocultured at a 2:1 effector-to-target ratio for 24 h. The T cells were stimulated using the anti-CD3a antibody (1 μg/mL, Biolegend, San Diego, CA, USA, Clone 145-2C11). .. To explore the interaction mechanism between CD4 + and CD8 + T cells, the cells were separately cultured in 0.4 μm Transwell chambers, or the following were added: CD11a (LFA-1alpha) monoclonal antibody (5 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone M17/4), CD54 (ICAM-1) monoclonal antibody (10 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone YN1/1.7.4), recombinant mouse IL-2 (100 IU/mL, novoprotein, Suzhou, China, P04351), InVivoMAb anti-mouse IL-2 (15 μg/mL, Bioxcell, Lebanon, NH, USA, Clone JES6-5H4), STAT5 inhibitor BD750 (10 μM, MedChemExpress, Monmouth Junction, NJ, USA), or Article Title: LFA-1/ICAM-1 Interactions Between CD8 + and CD4 + T Cells Promote CD4 + Th1-Dominant Differentiation and CD8 + T Cell Cytotoxicity for Strong Antitumor Immunity After Cryo-Thermal Therapy. Article Snippet: CD4+ and CD8+ T lymphocytes extracted from CTT-treated mice on the fifth day post-CTT were cocultured at a 2:1 effector-to-target ratio for 24 h. The T cells were stimulated using the anti-CD3a antibody (1 μg/mL, Biolegend, San Diego, CA, USA, Clone 145-2C11). .. To explore the interaction mechanism between CD4+ and CD8+ T cells, the cells were separately cultured in 0.4 μm Transwell chambers, or the following were added: CD11a (LFA-1alpha) monoclonal antibody (5 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone M17/4), CD54 (ICAM-1) monoclonal antibody (10 μg/mL, Thermo Fisher Scientific, Waltham, MA, USA, Clone YN1/1.7.4), recombinant mouse IL-2 (100 IU/mL, novoprotein, Suzhou, China, P04351), InVivoMAb anti-mouse IL-2 (15 μg/mL, Bioxcell, Lebanon, NH, USA, Clone JES6-5H4), STAT5 inhibitor BD750 (10 μM, MedChemExpress, Monmouth Junction, NJ, USA), or |